Decapeptide GnRH antagonist (D-Nal⁶ substitution and acetylated N-terminus) developed from ovine GnRH-antagonist templates. In controlled ovarian stimulation, direct GnRH-R blockade prevents the premature LH surge without the 2-week agonist down-regulation protocol — enabling shorter IVF cycles. Single 3 mg dose covers ~4 days; multiple 0.25 mg daily doses dial the antagonism more precisely.
Half-Life & Elimination Curve (SC: 63h)
Plasma (SC)t½ Decay (63h)
0×t½0h100%(34.1 µg/L)
1×t½63h50%(17 µg/L)
2×t½5.3d25%(8.52 µg/L)
3×t½7.9d12.5%(4.26 µg/L)
4×t½10.5d6.3%(2.13 µg/L)
5×t½13.1d3.1%(1.07 µg/L)
Elimination t½63h (SC)
Rate Constant (ke)0.011 h⁻¹
Time to Peak (Tmax)6.03h
Est. Peak (Cmax)34.1 µg/L
Clearance (CL)0.77 L/h
97% Washout (5×t½)13.1d
Dosing Guidelines
Subcutaneous (SC): Typical 3 mg
Pharmacokinetic Parameters
Subcutaneous (SC): Bioavailability (F): 85% · Volume of Distribution (Vd): 70 L · Absorption (ka): 0.7 h⁻¹ (t½ka ≈ 59m) [PMID 9806255]